Kala Pharmaceuticals, Inc. (KALA)
| Market Cap | 23.71M |
| Revenue (ttm) | 8.40M |
| Net Income (ttm) | -136.75M |
| Shares Out | 73.21M |
| EPS (ttm) | -2.14 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 380,333 |
| Open | 0.325 |
| Previous Close | 0.331 |
| Day's Range | 0.316 - 0.335 |
| 52-Week Range | 0.281 - 3.610 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 2.36 (+628.6%) |
| Earnings Date | Aug 11, 2022 |
About KALA
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative infl... [Read more...]
Financial Performance
In 2021, KALA's revenue was $11.24 million, an increase of 76.67% compared to the previous year's $6.36 million. Losses were -$142.61 million, 36.7% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for KALA stock is "Buy." The 12-month stock price forecast is 2.36, which is an increase of 628.62% from the latest price.
News
Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, development ...
Kala Pharmaceuticals (KALA) Reports Q2 Loss, Misses Revenue Estimates
Kala Pharma (KALA) delivered earnings and revenue surprises of 13.64% and 18.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Received $60M Upfront Payment from Sale of EYSUVIS® and ...
Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August
ARLINGTON, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of i...
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ARLINGTON, Mass., July 22, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement awar...
Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc
ARLINGTON, Mass, July 11, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of in...
Kala Pharma (KALA) Moves to Buy: Rationale Behind the Upgrade
Kala Pharma (KALA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Kala Pharmaceuticals to Present at Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Why Kala Pharmaceuticals Shares Are Rising Today
Kala Pharmaceuticals Inc (NASDAQ: KALA) shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for $60 million. Kala Pharmaceuticals is selling its commercial...
Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.
--Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments-- --Kala Will Focus Resources on Phase 2/3 Trial of KPI-012 for Orphan Disease Persisten...
Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates
Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives -
Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call
ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of i...
Kala Pharmaceuticals Posts KPI-012 Data In Healing Impaired Ocular Diseases
Kala Pharmaceuticals Inc (NASDAQ: KALA) reported data from a Phase 1b trial of KPI-012, a cell-free secretome therapy for severe ocular diseases driven by impaired healing. As previously disclosed, KPI...
Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treat...
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up -- -- All Patients with ...
Kala Pharmaceuticals (KALA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue Estimates
Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-- Achieved $11.2 Million in Net Revenue in 2021 -- -- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives -- -- KPI-012 Phase 1b Clinical Data Accepted for Pre...
Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of...
This Microcap Pharma Stock Almost Doubled Today - Read Why
UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ: KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022. E...
Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know
Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kala Pharma Acquires Ocular Surface Disease-Focused Company
Kala Pharmaceuticals Inc (NASDAQ: KALA) has acquired Combangio Inc, a private company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a secreto...
Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates
Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-- Achieved $3.1 Million in Net Revenue in 3Q 2021 -- -- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021 -- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio -- -- Conferenc...